| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.11 | 0.5 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.039 | 0.5 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |